AUTHORS
Yiqiu Zheng, Lixia Zhu2, Jimin Shi3, Yi Luo4, Yeqian Zhao5, Weiyan Zheng6, Jie Sun, PhD7, Xiu-Jin Ye8, Jian Yu9, Lizhen Liu10, Yang Cao, MD11, Xiaoyu Lai12, Xiaoxia Hu, MD13, Wei Shi14, He Huang, MD, PhD15, Yanmin Zhao, MD16
AFFILIATIONS
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
4 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
7 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
8 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
9 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
10 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
11 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
13 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
14 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
16 Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
ABSTRACT
Introduction
RUNX1-mutated acute myeloid leukemia (AML) is biologically heterogeneous and is frequently associated with myelodysplasia-related disease features. Although venetoclax-based regimens are increasingly used in this population, their comparative effectiveness relative to intensive chemotherapy remains uncertain. Thus, we compared frontline outcomes among patients with newly diagnosed RUNX1-mutated AML treated with venetoclax plus a hypomethylating agent (Ven+HMA), intensive chemotherapy (IC), or venetoclax plus intensive chemotherapy (Ven+IC).
Methods
We retrospectively identified consecutive adults with newly diagnosed RUNX1-mutated AML treated at four centers in China between 2017 and 2025. Patients with de novo or secondary AML who received frontline Ven+HMA, IC, or Ven+IC were included. Patients with myelodysplastic syndromes or mixed-phenotype acute leukemia were excluded. RUNX1 and co-occurring mutations were assessed by next-generation sequencing at diagnosis. The primary endpoint was composite complete remission (cCR), defined as complete remission or complete remission with incomplete hematologic recovery. Measurable residual disease (MRD)-negative cCR, defined as cCR with no detectable MRD by multiparameter flow cytometry at the end of induction, was assessed as a secondary endpoint. Generalized propensity-score overlap weighting was used to balance prespecified baseline treatment-selection factors across the three groups. Weighted logistic regression was used to compare cCR, and OS was measured from treatment initiation.
Results
Among 286 patients with newly diagnosed RUNX1-mutated AML, 123 received Ven+HMA, 113 received IC, and 50 received Ven+IC. The median age was 55.8 years. Overall, 252 patients had de novo AML and 34 had secondary AML. Patients receiving Ven+HMA were older and more frequently had secondary AML and myelodysplasia-related gene mutations. After overlap weighting, all prespecified baseline covariates were balanced, with absolute standardized mean differences <0.10. The adjusted cCR rates were 41.69% with IC, 65.08% with Ven+HMA, and 50.25% with Ven+IC (overall P=0.015). The adjusted MRD-negative cCR rates were 28.92% with IC, 52.17% with Ven+HMA, and 44.73% with Ven+IC (overall P=0.014). Compared with IC, Ven+HMA was associated with higher odds of achieving cCR (adjusted OR, 2.98; 95% CI, 1.54–5.78; P=0.001), whereas Ven+IC was not associated with a statistically significant difference in cCR (adjusted OR, 1.52; 95% CI, 0.72–3.21; P=0.266). In a multivariable sensitivity analysis, the association between Ven+HMA and cCR remained significant (adjusted OR, 2.93; 95% CI, 1.47–5.84; P=0.002).
Using intermediate RUNX1 VAF (>30% to 60%) as the reference, low RUNX1 VAF (≤30%) was associated with higher odds of cCR (adjusted OR, 2.39; 95% CI, 1.19–4.78; P=0.014), whereas the odds of cCR were similar for patients with high RUNX1 VAF (>60%) (adjusted OR, 1.02; 95% CI, 0.73–3.54; P=0.964).RAS–MAPK pathway mutations were independently associated with lower odds of achieving cCR (adjusted OR, 0.45; 95% CI, 0.24–0.84; P=0.012). The treatment effect directionally favored Ven+HMA across all prespecified subgroups, with no statistically significant treatment-by-subgroup interaction.
At the data cutoff, the median follow-up from treatment initiation was 22 months (95% CI, 19–26 months). During follow-up, 57.1%, 28.5%, and 60.8% of patients in the IC, Ven+HMA, and Ven+IC groups, respectively, underwent allo-HSCT. In a multivariable Cox model treating allo-HSCT as a time-dependent covariate, Ven+IC was associated with inferior OS compared with IC (adjusted HR, 1.92; 95% CI, 1.06–3.48; P=0.032), whereas OS did not differ significantly between Ven+HMA and IC (adjusted HR, 1.66; 95% CI, 0.95–2.91; P=0.073). Allo-HSCT was independently associated with improved OS (adjusted HR, 0.40; 95% CI, 0.22–0.72; P=0.002), whereas transcription-factor gene mutations were independently associated with inferior OS (adjusted HR,1.83; 95% CI, 1.16–2.9; P=0.010).
Conclusion
Frontline Ven+HMA was associated with higher odds of achieving cCR than IC in patients with newly diagnosed RUNX1-mutated AML. Overall survival was not significantly different with Ven+HMA. Allo-HSCT was independently associated with improved OS. These findings support Ven+HMA as an effective frontline option for RUNX1-mutated AML and warrant prospective validation.
DISCLOSURES
Yiqiu Zheng: No relevant conflicts of interest to declare.